Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from NeOnc Technologies Holdings, Inc. ( (NTHI) ).
On February 27, 2026, NeOnc Technologies Holdings, Inc. announced it will host an investor conference call and webcast on March 4, 2026, to present initial data from the Phase 1 dose-escalation portion of its NEO212-01 Phase 1/2 clinical trial. The event will feature NeOnc’s management team and independent members of its Scientific Advisory Board, including leading neuro-oncology experts from Duke University and NYU Langone Health.
During the call, the company plans to discuss safety and toxicity data, dose-escalation observations, and pharmacokinetic findings for its oral bioconjugated temozolomide platform in patients with CNS malignancies. The planned update, which will also outline regulatory next steps for NEO212, signals a key milestone in NeOnc’s clinical development program and may help clarify the risk profile and potential path forward for its CNS cancer therapy platform for investors and clinical stakeholders.
The most recent analyst rating on (NTHI) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on NeOnc Technologies Holdings, Inc. stock, see the NTHI Stock Forecast page.
Spark’s Take on NTHI Stock
According to Spark, TipRanks’ AI Analyst, NTHI is a Neutral.
The score is held back primarily by weak financial fundamentals (large losses, negative equity, and heavier cash burn), partially offset by constructive technicals with the stock trading above key moving averages and moderate momentum. Valuation is also a drag due to the negative P/E and lack of dividend yield.
To see Spark’s full report on NTHI stock, click here.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences and biopharmaceutical company focused on developing and commercializing central nervous system therapeutics designed to overcome the blood-brain barrier. Its NEO drug development platform has generated proprietary chemotherapy agents, including NEO100 and NEO212, which are in Phase II human clinical trials under FDA Fast-Track and IND status, supported by an exclusive worldwide patent portfolio licensed from the University of Southern California.
The company’s pipeline targets various oncological and neurological conditions, with its drug candidates and delivery methods protected by patents extending to 2038. NeOnc’s therapies have shown positive effects in preclinical studies across several cancer types and in clinical settings treating malignant gliomas, positioning the firm as an emerging player in CNS cancer treatment innovation.
Average Trading Volume: 62,727
Technical Sentiment Signal: Strong Buy
Current Market Cap: $220.1M
For detailed information about NTHI stock, go to TipRanks’ Stock Analysis page.